Oops...
No slides found, please add some slides

Milken Institute Kidney Disease Scientific Advisory Group Includes AAKP President Paul T. Conway

[vc_row][vc_column][vc_column_text]

FOR IMMEDIATE RELEASE
November 3, 2016

FOR MORE INFORMATION:
Sarah McConnell
Marketing & Communications Manager
813-400-2394
smcconnell@aakp.org

&nbsp
&nbsp

Milken Institute Kidney Disease Scientific Advisory Group Includes AAKP President Paul T. Conway

 Shares Personal and Policy Insights At “Call to Action Retreat”

New York, NY: On October 27-28, 2016, American Association of Kidney Patients (AAKP) Paul T. Conway participated in the Milken Institute ESRD Call to Action Retreat as a member of the Milken Institute Kidney Disease Scientific Advisory Group. Conway joined some of the nation’s leading philanthropists, medical experts, academics, pioneers in medical device and biologic technologies and patient advocacy organizations at a New York City meeting sponsored by the Milken Institute. Research from the retreat will inform future efforts in the field of kidney disease under consideration by the Milken Institute.

“The Milken Institute is a nationally recognized leader in the field of effective philanthropic investment, opportunity identification and the leveraging of donor funds to produce substantive solutions and breakthroughs in medicine,” said Paul T. Conway, president of AAKP and a former Chief of Staff of the United States Department of Labor.  “Government alone cannot solve the complex issue of kidney disease, so we welcome the opportunity to join with the Milken Institute and our allied organizations in an effort to highlight areas of underinvestment, elevate high impact solutions and work to transform disease treatment and patient outcomes.”

Conway presented at the session “Improving Dialysis Outcomes – The Path Forward.” He joined William Fissell, MD, Associate Professor, Nephrology and Hypertension, Vanderbilt University and Laura Dember, MD, Professor of Medicine and Epidemiology, Renal, Electrolyte and Hypertension Division, University of Pennsylvania School of Medicine. Conway drew on his personal experience, having managed kidney disease for over 36 years including 13 years of end-stage-renal disease, over two years of dialysis treatment and over 19 years as a kidney transplant recipient, as well as his policy expertise having served in multiple roles under three presidents and two governors, including two years as Virginia’s Deputy Director of Health and Human Services.

“Kidney disease threatens the dreams, aspirations and careers of those who are diagnosed and results in multiple costs to patients, communities and ultimately the entire nation. Fortunately, for kidney patients and for the future of medical innovation, government is not relied upon as the sole innovator on behalf of kidney patients. Many brilliant, selfless philanthropists with the courage, means and empathy to advocate and drive medical breakthroughs are at the helm, leading the way to better outcomes for some of our most vulnerable populations,” added Conway.

For more information about AAKP and its programs, visit www.aakp.org or call 1-800-749-2257.

###

Founded in 1969, AAKP is the largest and oldest independent kidney patient organization in America. Governed by a patient-majority Board of Directors, AAKP conducts national education programs designed to better inform kidney patients, care-givers and policy-makers about the true impacts of kidney disease, prevention efforts and treatment methods. AAKP publishes RenalLife Magazine which has a circulation of over 20,000 and appears in over 5,000 dialysis centers. The organization executes a national advocacy strategy in conjunction with allied kidney organizations designed to insert the patient voice into proposed policies, research efforts and care deliberations before the Executive Branch and the U.S. Congress.

 [/vc_column_text][/vc_column][/vc_row]